(Q34449123)

2 August 2017

1 reference

title

Treatment of Wegener's granulomatosis. (English)

1 reference

2 August 2017

Regan MJ

1

1 reference

PubMed ID

11723769

2 August 2017

Hellmann DB

series ordinal

2

1 reference

PubMed ID

11723769

2 August 2017

Stone JH

series ordinal

3

1 reference

2 August 2017

1 November 2001

1 reference

Rheumatic Diseases Clinics of North America

2 August 2017

1 reference

2 August 2017

27

1 reference

2 August 2017

4

1 reference

2 August 2017

863-86, viii

1 reference

Cyclosporin A therapy for Wegener's granulomatosis

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The development of mesna for regional detoxification

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener's granulomatosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Limited forms of angiitis and granulomatosis of Wegener's type

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The role of superantigens in vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Empiricism and Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Effect of Cyclophosphamide upon the Immune Response in Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Combined treatment in Wegener's granulomatosis with crescentic glomerulonephritis--clinical course and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Wegener's granulomatosis: isolated involvement of the trachea and larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Update on the European Vasculitis Study Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Intravenous immunoglobulin as sole therapy for systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Treatment of systemic vasculitis with pooled intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Intravenous immunoglobulin in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Antithymocyte globulin treatment of orbital Wegener granulomatosis: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The management of subglottic stenosis in patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

New approaches to treatment in systemic vasculitis: biological therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Approaches to specific immunotherapy for systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Wegener's granulomatosis: otorhinolaryngological manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Relapses in Wegener's granulomatosis: the role of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Treatment of Wegener's granulomatosis with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Wegener granulomatosis in children and adolescents: clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Use of mesna to prevent ifosfamide-induced urotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Renal toxicity of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Current therapies for systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

Cyclosporine, FK-506, rapamycin, and other immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970240-4

7 January 2021

10.1016/S0889-857X(05)70240-4

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11723769